17-63437504-T-A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001915.4(CYB561):c.44A>T(p.Tyr15Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001915.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYB561 | NM_001915.4 | c.44A>T | p.Tyr15Phe | missense_variant | 2/6 | ENST00000360793.8 | NP_001906.3 | |
CYB561 | NM_001330421.2 | c.65A>T | p.Tyr22Phe | missense_variant | 2/6 | NP_001317350.1 | ||
CYB561 | NM_001017916.2 | c.44A>T | p.Tyr15Phe | missense_variant | 2/6 | NP_001017916.1 | ||
CYB561 | NM_001017917.2 | c.44A>T | p.Tyr15Phe | missense_variant | 2/6 | NP_001017917.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 10, 2023 | The c.44A>T (p.Y15F) alteration is located in exon 2 (coding exon 1) of the CYB561 gene. This alteration results from a A to T substitution at nucleotide position 44, causing the tyrosine (Y) at amino acid position 15 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.